Frag' FlorenceEvidenz. Klar. Anwendbar.
Uhr 7/8Sources Journal Tree
Easy Demo

Florence Themenbrowser · Onkologie · Seite 18

Was ist neu im Gesundheitswesen?

Entdecken Sie tatsächlich neu veröffentlichte Arbeiten aus Medizin, Pflege, Therapie, Public Health und Life Sciences. Sortiert nach Publikationsdatum, nicht nach Zitierhäufigkeit.

Themen erkunden

Aktuelle Forschung nach Fachgebiet

23 neue Nachweise auf dieser Seite Publiziert in den letzten 30 Tagen Neueste zuerst Crossref DOI
27.08.2026journal-article

The Oncologist

Osimertinib plus anlotinib in untreated, EGFR-mutated, advanced non-small-cell lung cancer with concurrent alterations: a multicenter phase II study

Xiaojun Yang, Qinquan Tan, Shiyuan Chen, Jieyun Xie, Yihong Zeng, Ruinian Zheng, Qinglin Tan, Wan Zhang, Churen Yu, Ziying Hong, Xinpei Yu, Guanming Jiang

Abstract Background The standard first-line treatment for advanced EGFR-mutated non-small cell lung cancer (NSCLC) is EGFR tyrosine kinase inhibitors. However, concurrent mutations facilitate resistance evolution in EGFR-mutant lung adenocarcinoma and combination therapies may offer a superior approach. This study explores the efficacy and safety of osimertinib plus anlotinib as first-line treatment for advanced NSCLC with EGFR co-mutations. Materials and Methods This study prospectively enrolled patients with adva …

27.08.2026journal-article

Inquiry@Queen's Undergraduate Research Conference Proceedings

The Quality of Research Methods in Studies Quantifying the Association Between Cancer Diagnosis to Treatment Interval and Overall Survival

Vidhi Patel

Background and Objective: Studies examining the association between cancer diagnosis to treatment interval (DTI) and overall survival (OS) are important to help inform clinical practice guidelines. Recent international consensus-based recommendations defined best practices for this area of research and raised concerns about the poor validity and inconsistent methodologies in the available literature. Our objective is to systematically assess the quality of studies investigating the association between DTI and OS us …

27.08.2026journal-article

BMC Cancer

miR-451a is a differentially expressed blood-based microRNA in newly diagnosed CML identified by high-throughput profiling

Surbhi Gupta, Nitu Nigam, Abdullah H. Maad, Ninar AlJerf, S. P. Verma, Swasti Sinha, Rashmi Kushwaha, Manish Kumar Singh, Arun Kumar Trivedi, Soniya Nityanand, Muaaz Alajlani, Loai Aljerf

Abstract Background microRNAs (miRNAs) are emerging as promising biomarkers in hematological malignancies due to their stability in blood. This study aimed to investigate the differential expression of miRNAs in chronic myeloid leukemia (CML) and evaluate the potential of miR-451a as a candidate whole-blood miRNA marker. Methodology We collected whole blood samples from 77 newly diagnosed CML patients before TKI therapy and 77 healthy controls. A subset of samples underwent miRNA sequencing to identify dysregulated …

27.08.2026journal-article

Cancer Medicine

UTMD Suppresses CSF ‐1 to Drive Macrophage‐Mediated Ferroptosis in Papillary Thyroid Carcinoma

Yanqiang Niu, Zhenqiang Yao, Minghua Zhang, Jiayan Zhang, Yushan Li, Jinhui Xie, Zubang Zhou

ABSTRACT The tumor microenvironment (TME) of Papillary Thyroid Carcinoma (PTC), particularly the role of tumor‐associated macrophages (TAMs), contributes to therapeutic resistance. This study investigated whether ultrasound‐targeted microbubble destruction (UTMD), a non‐invasive physical modality, could reprogram the TME through modulation of TAMs and induction of ferroptosis. Transcriptomic profiling identified CSF‐1 as a top target suppressed by UTMD, which was validated by ELISA, Western blot, and qRT‐PCR. UTMD …

27.08.2026journal-article

Journal of Clinical Medicine

EZH2 Expression and Clinical Outcomes in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Retrospective Cohort Study

Esra Asarkaya, Hatice Asoglu, Abdurrahman Aykut, Gunes Dorukhan Cavusoglu, Yasemin Aydınalp, Sendag Yaslıkaya, Suheda Atas Ipek, Fatma Calkan, Emine Kilic Bagir, Derya Gumurdulu, Hulya Binokay, Tolga Koseci, Ismail Oguz Kara, Berksoy Sahin, Ertugrul Bayram

Background: Lung cancer remains the leading cause of cancer-related mortality, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases. Over the past decade, immune checkpoint inhibitors have become a core component of first-line treatment for advanced-stage NSCLC lacking driver mutations. Programmed death-ligand 1 (PD-L1) expression is currently used as the standard biomarker, yet its predictive value remains limited, and in most immunotherapy trials, treatment efficacy has been observed …

27.08.2026journal-article

Cancer Research

Chronic Stress–Induced m7G Cap Modification of ADRB2 Dysregulates the Pentose Phosphate Pathway to Promote Esophageal Squamous Cell Carcinoma Progression

Zihan Zhang, Feifei Liu, Peng Wang, Ting Wang, Xiangyu Wang, Rui Wang, Xiaodan Shi, Ruixia Zou, Ludan Jia, Xing Wei, Zhibo Li, Yankan Yu, HaiBo Sun, Dong Joon Kim, Simin Zhao, Zigang Dong

Abstract Chronic stress is increasingly recognized as a driver of cancer metabolism, highlighting the need to elucidate the mechanism linking chronic stress to metabolic reprogramming. In this study, we performed untargeted metabolomics on serum samples from patients with esophageal squamous cell carcinoma (ESCC) and integrated the results with clinical and stress-related assessments, revealing pentose phosphate pathway (PPP) enrichment accompanied by elevated epinephrine levels in patients with stress-associated f …

27.08.2026journal-article

Cancer Research

A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells

Bo-Reum Kim, Hyemin Kim, Hoon Choi, Daehun Kwag, Yoon-Ju Kim, Hyunsong Son, Sohyun Park, Jisu Park, Hadong Kim, Woosuk Choi, Seunghoon Lee, Hee-Je Kim, Hyunseok Kang, Hyunsun Jo, Byung-Sik Cho

Abstract Casein kinase 1α (CK1α) is a multifunctional serine/threonine kinase, serving as an upstream regulator of the p53 pathway and a potential therapeutic target for acute myeloid leukemia (AML). Small-molecule degraders show preclinical promise in AML by selectively degrading target proteins. In this study, we developed and evaluated PinA1, a molecular glue degrader targeting CK1α, in preclinical AML models. PinA1 preferentially degraded CK1α at nanomolar concentrations, resulting in enhanced p53 expression, c …

27.08.2026journal-article

World Journal of Surgical Oncology

Modified Albert–Lembert coloanal anastomosis with diverting ileostomy versus Turnbull–Cutait pull-through delayed coloanal anastomosis after intersphincteric resection for low rectal cancer: a single-center retrospective comparative study

Mengzhe Li, Hong Liang, Xi Wang, Zhanpeng Yang, Longshuai Yang, Gaojie Lian, Jianhui Li, Qingwen Fan, Chao Zhang

Abstract Background Reconstruction after intersphincteric resection (ISR) for low rectal cancer remains technically challenging. Turnbull–Cutait pull-through delayed coloanal anastomosis (DCAA) has been used as a sphincter-preserving delayed reconstructive strategy, but it requires exteriorization of the colon and a planned second-stage perineal procedure. To improve anastomotic stability after ISR, we performed modified Albert–Lembert coloanal anastomosis (MALA) with diverting ileostomy. This study aimed to compar …

27.08.2026journal-article

Neuro-Oncology

53 Analysis of translational challenges across 19 brain tumour therapeutic development programmes: Insights from the BTR-NTA accelerator

Kate Munro, Eloise Lines, Nicky Huskens, Katie Bushby, Karen Noble, Paul Brennan, Helen Bulbeck, Petra Hamerlik, Darren Hargrave, Edward Kaye, Dione Kobayashi, Ryan Mathew, Javad Nazarian, Ruman Rahman, Artie Romero, Erik Sulman, Juanita Lopez, Kanneboyina Nagaraju

Abstract Introduction Development of novel therapies for brain tumours faces high attrition rates, with few programmes reaching approval. This thematic analysis synthesises translational challenges identified through the Brain Tumour Research Novel Therapeutics Accelerator (BTR-NTA), an international multidisciplinary programme providing structured expert guidance to accelerate novel brain tumour treatments toward clinical application. Methods Between 2023 and 2025, BTR-NTA received 33 applications from academic an …

27.08.2026journal-article

Neuro-Oncology

31 CD44-Gal9 Interaction between IDH1-mutant Grade 4 Astrocytoma and Microglia Promotes Invasion and Proliferation of Tumor Cells

Nathalie Große, Felix Sahm, Christel Herold-Mende, Şevin Turcan

Abstract Introduction IDH1-mutant grade 4 astrocytomas exhibit pronounced interactions with the tumor microenvironment that critically influence tumor progression. Tumor-associated microglia/macrophages (TAMs) are key mediators of these interactions, yet the molecular mechanisms governing tumor-TAM crosstalk remain incompletely understood. Here, we investigated the role of CD44-Galectin-9 (Gal9) signaling in patient-derived IDH1-mutant astrocytoma models. Method scRNA-seq was performed on paired primary and recurre …

27.08.2026journal-article

Neuro-Oncology

67 Limited-stage small cell lung cancer – how to address the high risk of intracranial metastases?

Dina Saleh, Waleed Mohammed

Abstract Introduction Small cell lung cancer (SCLC) accounts for approximately 15% of lung cancers and is characterised by rapid proliferation, early dissemination and poor prognosis. It has a strong predilection for brain metastases, with around 10% of patients presenting with intracranial disease. Current standard of care recommends prophylactic cranial irradiation (PCI) for patients with limited-stage (LS) SCLC who respond to initial therapy. However, scrutiny of practice in the modern era does not necessarily r …

27.08.2026journal-article

Molecular Cancer Therapeutics

Structural basis and preclinical efficacy of MG1124, a novel CEACAM1-targeting antibody synergizing with PD-1 blockade

Jae-Chul Lee, Miyoung Oh, Hye-mi Nam, Hyun-Jung Cho, Jae Hwan Kim, Byoung Chul Cho, Seonghoon Kim, Byung-Ha Oh, Chang-Woo Lee

Abstract CEACAM1 homodimerization mediates tumor immune evasion, presenting a compelling target to overcome resistance to PD-1 blockade. However, defining a precise structural and pharmacological blueprint for CEACAM1 targeting has remained challenging. Here, we report the discovery and comprehensive preclinical characterization of MG1124, a highly specific, fully human monoclonal antibody targeting the CEACAM1 IgV domain. X-ray crystallographic analysis at a 1.8 Å resolution revealed that MG1124 binds the homodime …

27.08.2026journal-article

Revista Científica Saúde Global

Strategies in the Prevention and Treatment of Obesity

Ieda Carla Candido, Gisele Nicchio Rocha Buzzo, Matheus Rodrigues Dos Santos, Rafaela Crystina Vieira Bonfim, Fernanda Aparecida Vicente Magalhães, Karine Oltramari, Paulo Cesar Franzini, Angélica Sbrolini Marques Mincache, Greice Westphal-Nardo, Nelson Nardo Júnior Nardo Júnior

Objective: This study aims to present the most recent advances and the challenges encountered in the provision of pharmacological, surgical, and multidisciplinary programs for the treatment of obesity. Methods: This is a narrative literature review with a qualitative and exploratory approach, conducted in July 2025. The theoretical framework was based on studies published between 2020 and 2025, focusing on strategies for obesity prevention and treatment, particularly pharmacological therapies, bariatric surgery, an …

27.08.2026journal-article

Frontiers in Medicine

Endoscopic drainage and one-stage titanium clip closure for appendiceal root abscess mimicking cecal submucosal tumor: a case report

Yanping Dai, Yang Liu, Jun Ye

Periappendiceal abscess stands as a frequent complication stemming from acute appendicitis. One rare variant presents as a submucosal mass at the root of the appendix and cecum. Clinicians often misdiagnose this form at alarmingly high rates. Conventional management brings substantial surgical trauma. It also prolongs patients’ recovery periods. Whether minimally invasive endoscopic intervention works well for this distinct abscess subtype still lacks solid clinical proof. Whether minimally invasive endoscopic inte …

27.08.2026journal-article

Journal of Human Hypertension

Antihypertensive treatment and adverse psychiatric reactions in primary health care

Emina Curic, Henrik Ohlsson, Kenneth Kendler, Jan Sundquist, Kristina Sundquist, Margareta Reis, Bengt Zöller

Abstract Antihypertensive treatment (AHT) has been associated with adverse psychiatric reactions (APRs), but existing data are conflicting. The aim of the present study was to determine the risk for seven different APRs in drug-naive patients with newly diagnosed hypertension in primary health care. This cohort study analyzed registry data of individuals aged 40–70 with a newly diagnosed untreated hypertension without previous psychiatric or cardiovascular comorbidities in Swedish primary healthcare from 2006 and o …

27.08.2026journal-article

Journal of Clinical Oncology

Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS / BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial

Yu Sunakawa, Manabu Shiozawa, Takanori Watanabe, Hirofumi Ota, Hisateru Yasui, Taichi Yabuno, Mitsuyoshi Tei, Mitsugu Kochi, Dai Manaka, Hisatsugu Ohori, Tatsuro Yamaguchi, Tamotsu Sagawa, Masahito Kotaka, Yutaro Kubota, Takashi Sekikawa, Masato Nakamura, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii, Akihito Tsuji

The randomized phase II DEEPER trial (jRCTs061180022) previously reported superior depth of response with modified 5-fluorouracil, leucovorin, oxaliplatin and irinotecan (m-FOLFOXIRI) plus cetuximab versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer (mCRC). Here, we report updated final survival outcomes and exploratory subgroup analyses focusing on RAS / BRAF wild-type and left-sided tumors. Final overall survival (OS) and progression-free survival (PFS) were analyzed in the per-protoco …

27.08.2026journal-article

Cancer Medicine

Adjusted Risk Stratification of Indeterminate Thyroid Nodules Using the American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI‐RADS)

Jessica Zhao, Rita Abi‐Raad, Sara I. Pai, Jonathan Langdon, Minhua Wang, Guoping Cai, John Sinard, Adebowale J. Adeniran, Sanhong Yu

ABSTRACT Background The TI‐RADS guides the initial management of thyroid nodules, but the malignancy risk across different categories of cytologically indeterminate thyroid nodules (CITNs), particularly AUS and FN, remains unclear. Methods We reviewed thyroid FNA specimens diagnosed as AUS or FN with TI‐RADS scores of 3, 4, or 5 from 2017 to 2025. Clinical data, molecular results, and surgical outcomes were analyzed. Results A total of 919 CITNs were identified: 304 with TI‐RADS 3, 454 with TI‐RADS 4, and 161 with …

27.08.2026journal-article

Neuro-Oncology

58 Disrupting metabolic plasticity in glioblastoma stem-like cells via FABP7 inhibition and DHA supplementation

Cécilia Bernier, Seth Peyton, Cyrene Jonah Catenza, Won-Shik Choi, Abigail Hill, Liang Li, Hélène Lemieux, Roseline Godbout

Abstract Introduction Glioblastoma (GBM) is a brain cancer with high recurrence and poor remission rates despite intensive therapies. Treatment resistance is attributed to GBM stem-like cells (GSCs), which display high metabolic plasticity to adapt to environmental and therapeutic stress. GSCs express high levels of fatty acid-binding protein 7 (FABP7), which facilitates intracellular lipid transport. FABP7 binds docosahexaenoic acid (DHA), a polyunsaturated fatty acid with anti-tumorigenic properties in GSCs. Howe …

27.08.2026journal-article

Neuro-Oncology

14 Writing To Patients With Vestibular Schwannoma Transitioning from complexity to clarity leveraging Learning language model

Hina Kapadia, Andrew Kay, Luke Galloway

Abstract Introduction Effective written communication is central to patient-centred and safe care. NHS guidance recommends that outpatient clinic letters be written directly to patients at a readability level equivalent to Flesch Reading Ease (FRE) ≥60. However, neurosurgical correspondence often remains highly technical. Vestibular schwannoma (VS) management, involving complex decisions regarding surgery, radiotherapy, or surveillance, provides a suitable model to examine readability and evaluate whether large lan …

27.08.2026journal-article

Neuro-Oncology

18 TTFields with maintenance temozolomide/pembrolizumab versus TTFields with maintenance temozolomide/placebo for newly diagnosed glioblastoma: the phase 3 EF-41/KEYNOTE D58 trial

Gerben Borst, David D Tran, Ashley P Ghiaseddin, Michael Lim, Michael Weller, Motoo Nagane, Jacob C Easaw, Elizabeth Cohen-Jonathan Moyal

Abstract Introduction With the current standard-of-care for glioblastoma (maximal safe resection followed by radiotherapy with concurrent TMZ, then maintenance temozolomide/TTFields), median overall survival (OS) is approximately 21 months. Immune checkpoint inhibitors have not demonstrated meaningful clinical benefit in glioblastoma, partly because the tumor microenvironment is immunosuppressive. Preclinically, TTFields can induce immunogenic cell death and activate type 1 interferon signaling, with downstream inc …

27.08.2026journal-article

Particle & Particle Systems Characterization

A Sustainable Approach for Effective Antimicrobial and Antiproliferative Activity Against Cervical Cancer Cells Using Caesulia axillaris ‐Mediated Pt@Co 3 O 4 /rGO NCs

Pavan R. Bhilkar, Amit B. Nimje, Swapnil C. Kamble, Ankita R. Daddemal‐Chaudhary, Rupali R. Chaudhary, Shubham S. Tripathy, Konstantin Volcho, Subhash R. Somkuwar, Ratiram G. Chaudhary

ABSTRACT Herein, we report the biogenic synthesis of platinum‐doped cobalt oxide–reduced graphene oxide nanocomposites (Pt@Co 3 O 4 /rGO NCs) via green approach using Caesulia axillaris leaf extract as both reducing and capping agents for multiple biological applications. As‐biosynthesized NCs was characterized by various analytical techniques. The XRD study demonstrated the crystalline nature of materials with an average crystallite size of 2.1 nm, while TEM revealed particle sizes around 8–14 nm. The Raman study …

27.08.2026journal-article

Current Oncology

Tolerance and Efficacy of Targeted Therapies After Immunotherapy for Advanced Non-Small Cell Lung Cancers Harboring Oncogenic Alterations: The GFPC-TOXIMAD Study

Thomas Pierret, Jean-Bernard Auliac, Charles Ricordel, Catherine Daniel, Jessica Nguyen, Florian Guisier, Aurélie Swalduz, Hubert Curcio, Anne Laure Desage, Laurence Bigay-Game, Eric Huchot, Lionel Falchero, Hélène Doubre, Olivier Bylicki, Christos Chouaïd, Laurent Greillier

Background: The sequential use of anti-programmed cell death (ligand)-1 [PD-(L)1] immune-checkpoint inhibitors (ICIs) followed by targeted tyrosine-kinase inhibitors (TKIs) for advanced non-small cell lung cancer (NSCLC) with oncogenic alterations raises questions about tolerance and efficacy. Recent study results suggested an increased risk of adverse events (AEs) with this sequence. Methods: Multicenter retrospective study on advanced NSCLC patients treated with ICIs followed by targeted therapies between 2015 an …

27.08.2026journal-article

Frontiers in Medicine

RBPMS::NTRK3-rearranged sacral malignant spindle cell tumor in neurofibromatosis diagnosed by RNA sequencing: a case report and literature review

Chaopeng Chen, Bin Qi, Yuanyuan Miao, Zhujiang Zhuang, Chaowen Wang, Weiping Dai

Malignant spindle cell tumors arising in patients with neurofibromatosis are diagnostically challenging because malignant peripheral nerve sheath tumor (MPNST) and emerging NTRK-rearranged mesenchymal neoplasms may show overlapping clinical, histological, and immunophenotypic features. We report a 31-year-old man with a more than 20-year history of neurofibromatosis who presented with progressive lumbosacral pain and left lower-limb numbness. Imaging revealed a large cystic-solid sacral mass involving the S1–S2 reg …